Demonstrates immune activation in cancer cells using covalent aptamers, suggesting a novel therapeutic strategy.
Covalent aptamers have recently found initial success as tools for fast and selective transfer of labels to target proteins. Here, aptamers targeting protein tyrosine kinase 7 (PTK7) and the mesenchymal-epithelial transition factor (cMet) were functionalized with electrophiles capable of covalently transferring small-molecule immune recruiters. Capitalizing on biotin transfer, aptamers were utilized to trigger activation of universal anti-biotin chimeric antigen receptor (CAR) T cells resulting in selective lysis of PTK7- and cMet-positive cells. Additionally, a cleavable electrophile of 2,4-dinitrophenyl (DNP) hapten transfer was synthesized and utilized for the selective modification of cell surface PTK7 and cMet. The DNP modification elicited the selective activation of complement-dependent cytotoxicity (CDC). These results demonstrate the potential of covalent aptamers as immune-activating and cancer-cell-killing agents.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: